慢性肝炎肝硬化和肝衰竭患者吲哚菁绿清除试验的变化及其临床意义

doi:10.3969/j.issn.1672-5069.2021.01.024

摘要/Abstract

摘要： 目的探讨吲哚菁绿(ICG)清除试验对不同程度慢性肝病患者肝脏储备功能的评估价值。方法 2017年11月～2019年8月山西医科大学第一医院感染病科住院治疗的肝病患者87例,其中慢性病毒性肝炎9例,肝硬化69例,慢性肝衰竭9例,使用日本DDG-3300K分析仪及配套分析软件检测ICG15分钟滞留率(ICG-R15)、ICG血浆清除率(K值)和有效肝脏血流量(EHBF),同时检测肝功能、血常规、腹部彩超、腹部CT或MRI,计算肝功能Child-Turcotte-Pugh(CTP)评分并对肝硬化患者分级。结果慢性肝衰竭组ICG-R15为(54.2±11.6)%,K值为(0.04±0.01)/min,EHBF为(0.2±0.1)L/min,与慢性肝炎组比,差异显著【分别为(7.4±1.7)%、(0.22±0.05)/min和(0.9±0.3)L/min,P<0.05】;11例CTP C级患者ICG-R15为(39.3±8.9)%,K值为(0.06±0.02)/min,EHBF为(0.3±0.1)L/min,与39例CTP B级【分别为(28.8±12.6)%、(0.10±0.03)/min和(0.4±0.2)L/min,P<0.05】或19例CTP A级【分别为(12.2±2.8)%、(0.16±0.05)/min和(0.7±0.2)L/min,P<0.05】比,差异显著。结论 ICG清除试验能动态反映肝脏储备功能,弥补CTP分级的不足,尝试作为早期诊断肝硬化的参考指标,值得进一步研究。

关键词: 肝硬化, 肝衰竭, 吲哚菁绿清除试验, 肝脏储备功能, Child-Turcotte-Pugh 分级

Abstract: Objective The aim of this study was to estimate the changes and clinical significance of indocyanine green (ICG) clearance test in patients with chronic viral hepatitis, liver cirrhosis and liver failure. Methods A total of 87 patients with chronic liver diseases including chronic viral hepatitis in 9, liver cirrhosis in 69 and chronic liver failure in 9 were hospitalized in the Department of Infectious Diseases, First Hospital affiliated to Shanxi Medical University between November 2017 and August 2019. The ICG retention rate at 15 min(ICG-R15), ICG plasma clearance rate (K value) and effective hepatic blood flow (EHBF) were measured by DDG-3300K analyzer. Meanwhile, all the patients received blood hepatic functions, routine blood tests, abdominal color Doppler ultrasound, abdominal CT scan or MRI scan. The Child-Turcotte-Pugh(CTP) scores were calculated for classification. Results In patients with chronic liver failure, the ICG-R15 was (54.2±11.6)%, the K value was (0.04±0.01)/min, and the EHBF was (0.2±0.1)L/min, significantly different compared to 【(7.4±1.7)%, (0.22±0.05)/min and (0.9±0.3)L/min, respectivel, P<0.05】 in patients with chronic hepatitis; in 11 patients with liver cirrhosis CTP class C, the ICG-R15 was (39.3±8.9)%, the K was (0.06±0.02)/min, and the EHBF was (0.3±0.1)L/min, significantly different compared to【(28.8±12.6)%,(0.10±0.03)/min and (0.4±0.2)L/min, respectively,P<0.05】 in 39 cirrhotic patients with CTP class B or 【(12.2±2.8)%,(0.16±0.05)/min and (0.7±0.2)L/min, P<0.05】 in 19 patients with CTP class A.Conclusion The ICG clearance test could reflect liver reserve functions, and it might be a dynamic parameter for liver function evaluation if we test it often.

Key words: Liver cirrhosis, Liver failure, Indocyanine green clearance test, Liver reserve function, Child-Turcotte-Pugh classification

魏荣荣, 李爱玲, 李红, 张缭云. 慢性肝炎肝硬化和肝衰竭患者吲哚菁绿清除试验的变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 91-94.

Wei Rongrong, Li Ailing, Li Hong, et al. Changes and clinical significance of indocyanine green clearance test in patients with chronic viral hepatitis, liver cirrhosis and liver failure[J]. Journal of Practical Hepatology, 2021, 24(1): 91-94.

参考文献

[1] Solà E, Watson H, Graupera I, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol, 2012, 57(6):1199-1206.
[2] Haberl J, Zollner G, Fickert P, et al. To salt or not to salt? that is the question in liver cirrhosis.Liver Int, 2018, 38(7):1148-1159.
[3] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志, 2016, 19(3):389-400.
[4] 中华医学会肝病学分会, 中华医学会感染病学分会. 《丙型肝炎防治指南》2015年更新版. 实用肝脏病杂志, 2016, 19(4):521-538.
[5] 葛均波, 徐永健, 梅长林, 等. 内科学.8版. 北京:人民卫生出版社, 2013:419-428.
[6] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用肝脏病杂志, 2013, 16(3):210-216.
[7] Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med, 2007, 356(15):1545-1559.
[8] Pan Z, Wu XJ, Li JS, et al. Functional hepatic flow in patients with liver cirrhosis. World J Gastroenterol, 2004, 10(6):915-918.
[9] Kok B, Abraldes JG. Child-pugh classification: time to abandon?. Semin Liver Dis,2019, 39(1):96-103.
[10] Gallegos-Orozco JF, Vargas HE. Liver transplantation: from child to meld. Med Clin North Am, 2009, 93(4):931-950.
[11] Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res, 2009, 39(2):107-116.
[12] Poon RT, Fan ST. Assessment of hepatic reserve for indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg, 2005, 12(1):31-37.
[13] Halle BM, Poulsen TD, Pedersen HP. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. Acta Anaesthesiol Scand, 2014, 58(10):1214-1219.
[14] Audebert C, Vignon-Clementel IE. Model and methods to assess hepatic function from indocyanine green fluorescence dynamical measurements of liver tissue. Eur J Pharm Sci, 2018, 115:304-319.
[15] Cheng XP, Zhao J, Chen Y, et al. Comparison of the ability of the pdd-icg clearance test, ctp, meld, and meld-na to predict short-term and medium-term mortality in patients with decompensated hepatitis b cirrhosis. Eur J Gastroenterol Hepatol, 2016, 28(4):444-448.
[16] Wang YY, Zhao XH, Ma L, et al. Comparison of the ability of child-pugh score, meld score, and icg-r15 to assess preoperative hepatic functional reserve in patients with hepatocellular carcinoma. J Surg Oncol, 2018, 118(3):440-445.
[17] Shalimar, Jain S, Gamanagatti SR, et al. Role of indocyanine green in predicting post-transarterial chemoembolization liver failure in hepatocellular carcinoma. J Clin Exp Hepatol, 2018, 8(1):28-34.
[18] Yunhua T, Weiqiang J, Maogen C, et al. The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation. J Clin Monit Comput, 2018, 32(3):471-479.
[19] 刘义荣, 范作鹏, 杨薇, 等. 吲哚菁绿滞留测试对肝储备功能的评价. 中华肝脏病杂志, 2010, 18(6):476-477.
[20] Schwabl P, Mandorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in hiv/hcv patients with advanced liver disease. Aliment Pharmacol Ther, 2017, 45(1):139-149.
[21] Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with hcv-related decompensated cirrhosis: results from an Italian real-life cohort (liver network activity-lina cohort). Hepatol Int, 2019, 13(1):66-74.